Global Pediatric Drugs and Vaccines Market Overview And Scope:
Global Pediatric Drugs and Vaccines Market Size was estimated at USD 104273.71 million in 2022 and is projected to reach USD 175745.6 million by 2028, exhibiting a CAGR of 9.09% during the forecast period.
The Global Pediatric Drugs and Vaccines Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Pediatric Drugs and Vaccines utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Merck and Co., Inc. (USA), Abbott Laboratories (USA), Amgen, Inc. (USA), Eli Lilly and Company (USA), F. Hoffmann-La Roche Ltd (Switzerland), Genentech, Inc. (USA), GlaxoSmithKline plc. (UK), Janssen Biologics B.V. (USA), Actelion Pharmaceuticals, AstraZeneca Plc. (UK), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (USA), Allergan, Inc. (USA), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Pfizer, Inc. (USA), Sanofi S.A (France), Shionogi Inc. (USA), Takeda
Global Pediatric Drugs and Vaccines Market Segmentation
By Type, Pediatric Drugs and Vaccines market has been segmented into:Diphtheria
Influenza
Hepatitis
Pneumococcal Diseases
Meningococcal Diseases
Mumps
Others
By Application, Pediatric Drugs and Vaccines market has been segmented into:
Newborn
Infant
Child
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Pediatric Drugs and Vaccines market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Pediatric Drugs and Vaccines market.
Top Key Players Covered in Pediatric Drugs and Vaccines market are:
Merck and Co.
Inc. (USA)
Abbott Laboratories (USA)
Amgen
Inc. (USA)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech
Inc. (USA)
GlaxoSmithKline plc. (UK)
Janssen Biologics B.V. (USA)
Actelion Pharmaceuticals
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (USA)
Allergan
Inc. (USA)
Novartis AG (Switzerland)
Novo Nordisk A/S (Denmark)
Pfizer
Inc. (USA)
Sanofi S.A (France)
Shionogi Inc. (USA)
Takeda
Objective to buy this Report:
1. Pediatric Drugs and Vaccines analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Pediatric Drugs and Vaccines market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Pediatric Drugs and Vaccines Market by Type
5.1 Pediatric Drugs and Vaccines Market Overview Snapshot and Growth Engine
5.2 Pediatric Drugs and Vaccines Market Overview
5.3 Diphtheria
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Diphtheria: Geographic Segmentation
5.4 Influenza
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Influenza: Geographic Segmentation
5.5 Hepatitis
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Hepatitis: Geographic Segmentation
5.6 Pneumococcal Diseases
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Pneumococcal Diseases: Geographic Segmentation
5.7 Meningococcal Diseases
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Meningococcal Diseases: Geographic Segmentation
5.8 Mumps
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Mumps: Geographic Segmentation
5.9 Others
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 Others: Geographic Segmentation
Chapter 6: Pediatric Drugs and Vaccines Market by Application
6.1 Pediatric Drugs and Vaccines Market Overview Snapshot and Growth Engine
6.2 Pediatric Drugs and Vaccines Market Overview
6.3 Newborn
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Newborn: Geographic Segmentation
6.4 Infant
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Infant: Geographic Segmentation
6.5 Child
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Child: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Pediatric Drugs and Vaccines Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Pediatric Drugs and Vaccines Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Pediatric Drugs and Vaccines Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 MERCK AND CO.
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 INC. (USA)
7.4 ABBOTT LABORATORIES (USA)
7.5 AMGEN
7.6 INC. (USA)
7.7 ELI LILLY AND COMPANY (USA)
7.8 F. HOFFMANN-LA ROCHE LTD (SWITZERLAND)
7.9 GENENTECH
7.10 INC. (USA)
7.11 GLAXOSMITHKLINE PLC. (UK)
7.12 JANSSEN BIOLOGICS B.V. (USA)
7.13 ACTELION PHARMACEUTICALS
7.14 ASTRAZENECA PLC. (UK)
7.15 BOEHRINGER INGELHEIM GMBH (GERMANY)
7.16 BRISTOL-MYERS SQUIBB COMPANY (USA)
7.17 ALLERGAN
7.18 INC. (USA)
7.19 NOVARTIS AG (SWITZERLAND)
7.20 NOVO NORDISK A/S (DENMARK)
7.21 PFIZER
7.22 INC. (USA)
7.23 SANOFI S.A (FRANCE)
7.24 SHIONOGI INC. (USA)
7.25 TAKEDA
Chapter 8: Global Pediatric Drugs and Vaccines Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Diphtheria
8.2.2 Influenza
8.2.3 Hepatitis
8.2.4 Pneumococcal Diseases
8.2.5 Meningococcal Diseases
8.2.6 Mumps
8.2.7 Others
8.3 Historic and Forecasted Market Size By Application
8.3.1 Newborn
8.3.2 Infant
8.3.3 Child
Chapter 9: North America Pediatric Drugs and Vaccines Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Diphtheria
9.4.2 Influenza
9.4.3 Hepatitis
9.4.4 Pneumococcal Diseases
9.4.5 Meningococcal Diseases
9.4.6 Mumps
9.4.7 Others
9.5 Historic and Forecasted Market Size By Application
9.5.1 Newborn
9.5.2 Infant
9.5.3 Child
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Pediatric Drugs and Vaccines Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Diphtheria
10.4.2 Influenza
10.4.3 Hepatitis
10.4.4 Pneumococcal Diseases
10.4.5 Meningococcal Diseases
10.4.6 Mumps
10.4.7 Others
10.5 Historic and Forecasted Market Size By Application
10.5.1 Newborn
10.5.2 Infant
10.5.3 Child
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Pediatric Drugs and Vaccines Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Diphtheria
11.4.2 Influenza
11.4.3 Hepatitis
11.4.4 Pneumococcal Diseases
11.4.5 Meningococcal Diseases
11.4.6 Mumps
11.4.7 Others
11.5 Historic and Forecasted Market Size By Application
11.5.1 Newborn
11.5.2 Infant
11.5.3 Child
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Pediatric Drugs and Vaccines Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Diphtheria
12.4.2 Influenza
12.4.3 Hepatitis
12.4.4 Pneumococcal Diseases
12.4.5 Meningococcal Diseases
12.4.6 Mumps
12.4.7 Others
12.5 Historic and Forecasted Market Size By Application
12.5.1 Newborn
12.5.2 Infant
12.5.3 Child
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Pediatric Drugs and Vaccines Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Diphtheria
13.4.2 Influenza
13.4.3 Hepatitis
13.4.4 Pneumococcal Diseases
13.4.5 Meningococcal Diseases
13.4.6 Mumps
13.4.7 Others
13.5 Historic and Forecasted Market Size By Application
13.5.1 Newborn
13.5.2 Infant
13.5.3 Child
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Pediatric Drugs and Vaccines Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Diphtheria
14.4.2 Influenza
14.4.3 Hepatitis
14.4.4 Pneumococcal Diseases
14.4.5 Meningococcal Diseases
14.4.6 Mumps
14.4.7 Others
14.5 Historic and Forecasted Market Size By Application
14.5.1 Newborn
14.5.2 Infant
14.5.3 Child
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Pediatric Drugs and Vaccines Scope:
|
Report Data
|
Pediatric Drugs and Vaccines Market
|
|
Pediatric Drugs and Vaccines Market Size in 2025
|
USD XX million
|
|
Pediatric Drugs and Vaccines CAGR 2025 - 2032
|
XX%
|
|
Pediatric Drugs and Vaccines Base Year
|
2024
|
|
Pediatric Drugs and Vaccines Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Merck and Co., Inc. (USA), Abbott Laboratories (USA), Amgen, Inc. (USA), Eli Lilly and Company (USA), F. Hoffmann-La Roche Ltd (Switzerland), Genentech, Inc. (USA), GlaxoSmithKline plc. (UK), Janssen Biologics B.V. (USA), Actelion Pharmaceuticals, AstraZeneca Plc. (UK), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (USA), Allergan, Inc. (USA), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Pfizer, Inc. (USA), Sanofi S.A (France), Shionogi Inc. (USA), Takeda.
|
|
Key Segments
|
By Type
Diphtheria
Influenza
Hepatitis
Pneumococcal Diseases
Meningococcal Diseases
Mumps
Others
By Applications
Newborn
Infant
Child
|
